View Item 

Show simple item record

Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
dc.contributor.authorChow, Constance L.
dc.contributor.authorKadouh, Nour K.
dc.contributor.authorBostwick, Jolene R.
dc.contributor.authorVandenBerg, Amy M.
dc.date.accessioned2020-07-02T20:34:46Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-07-02T20:34:46Z
dc.date.issued2020-06
dc.identifier.citationChow, Constance L.; Kadouh, Nour K.; Bostwick, Jolene R.; VandenBerg, Amy M. (2020). "Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40(6): 565-574.
dc.identifier.issn0277-0008
dc.identifier.issn1875-9114
dc.identifier.urihttps://hdl.handle.net/2027.42/155998
dc.publisherCanadian Agency for Drugs and Technologies in Health
dc.publisherWiley Periodicals, Inc.
dc.subject.otherschizophrenia
dc.subject.otherakathisia
dc.subject.otherantipsychotics
dc.subject.otherbipolar disorder
dc.subject.othermajor depressive disorder
dc.titleAkathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155998/1/phar2404_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155998/2/phar2404.pdf
dc.identifier.doi10.1002/phar.2404
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
dc.identifier.citedreferenceNakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double‐blind, placebo‐controlled trial. J Clin Psychiatry 2009; 70 ( 6 ): 829 – 36.
dc.identifier.citedreferenceDavidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended‐release tablets (paliperidone ER): results of a 6‐week, randomized, placebo‐controlled study. Schizophr Res 2007; 93 ( 1 ): 117 – 30.
dc.identifier.citedreferenceKramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long‐acting treatment for patients with schizophrenia. Results of a randomized, double‐blind, placebo‐controlled efficacy and safety study. Int J Neuropsychopharmacol 2010; 13 ( 5 ): 635 – 47.
dc.identifier.citedreferenceNussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012;( 6 ): CD008296.
dc.identifier.citedreferenceTzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended‐release tablets in elderly patients with schizophrenia: a double‐blind, placebo‐controlled study with six‐month open‐label extension. Am J Geriatr Psychiatry 2008; 16 ( 1 ): 31 – 43.
dc.identifier.citedreferenceKomossa K, Rummel‐Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011;( 1 ): CD006626.
dc.identifier.citedreferenceRattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev 2016;( 12 ): CD006918.
dc.identifier.citedreferenceSampson S, Hosalli P, Furtado VA, Davis JM. Risperidone (depot) for schizophrenia. Cochrane Database Syst Rev 2016;( 4 ): CD004161.
dc.identifier.citedreferenceSachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double‐blind, placebo‐controlled trial. J Clin Psychiatry 2011; 72 ( 10 ): 1413 – 22.
dc.identifier.citedreferenceKomossa K, Rummel‐Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;( 4 ): CD006627.
dc.identifier.citedreferenceStudy Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone – Study Results – ClinicalTrials.gov. Available from https://clinicaltrials.gov/ct2/show/results/NCT00406315. Accessed April 26, 2019.
dc.identifier.citedreferenceKeck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4‐week placebo‐controlled trial. Psychopharmacology 1998; 140 ( 2 ): 173 – 84.
dc.identifier.citedreferenceDaniel D, Zimbroff D, Potkin S, Reeves K, Harrigan E, Lakshmirarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6‐week placebo‐controlled trial. Neuropsychopharmacology 1999; 20 ( 5 ): 491 – 505.
dc.identifier.citedreferenceKeck PE, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three‐week, placebo‐controlled, double‐blind, randomized trial. Am J Psychiatry 2003; 160 ( 4 ): 741 – 8.
dc.identifier.citedreferenceVieta E, Ramey T, Keller D, English P, Loebel A, Miceli J. Ziprasidone in the treatment of acute mania: a 12‐week, placebo‐controlled, haloperidol‐referenced study. J Psychopharmacol (Oxf) 2008; 24 ( 4 ): 547 – 58.
dc.identifier.citedreferenceBowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6‐month, randomized, placebo‐controlled, double‐blind trial. J Clin Psychiatry 2010; 71 ( 2 ): 130 – 7.
dc.identifier.citedreferenceCarnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001; 21 ( 6 ): 717 – 30.
dc.identifier.citedreferenceGao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic‐induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28 ( 2 ): 203 – 9.
dc.identifier.citedreferencePoyurovsky M. Acute antipsychotic‐induced akathisia revisited. Br J Psychiatry 2010; 196 ( 2 ): 89 – 91.
dc.identifier.citedreferenceBuckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo‐controlled trials. Curr Med Res Opin 2004; 20 ( 9 ): 1357 – 63.
dc.identifier.citedreferencePotkin SG, Gharabawi GM, Greenspan AJ, et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85 ( 1 ): 254 – 65.
dc.identifier.citedreferenceNasrallah HA, Brecher M, Paulsson B. Placebo‐level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disord 2006; 8 ( 5p1 ): 467 – 74.
dc.identifier.citedreferenceArvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiat 1997; 42 ( 4 ): 233 – 46.
dc.identifier.citedreferenceMiller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman J. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. Schizophrenia Res 1997; 1: 265 – 6.
dc.identifier.citedreferenceHirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003; 29 ( 3 ): 547 – 58.
dc.identifier.citedreferenceBarnes TRE. The Barnes Akathisia rating scale—revisited. J Psychopharmacol (Oxf) 2003; 17 ( 4 ): 365 – 70.
dc.identifier.citedreferenceKane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção‐Talbott S. Akathisia: an updated review focusing on second‐generation antipsychotics. J Clin Psychiatry 2009; 70 ( 5 ): 627 – 43.
dc.identifier.citedreferencePutten TV. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31 ( 1 ): 67 – 72.
dc.identifier.citedreferenceSeemüller F, Lewitzka U, Bauer M, et al. The relationship of akathisia with treatment emergent suicidality among patients with first‐episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry 2012; 45 ( 07 ): 292 – 6.
dc.identifier.citedreferenceSachdev PS. Neuroleptic‐induced movement disorders: an overview. Psychiatr Clin North Am 2005; 28 ( 1 ): 255 – 74.
dc.identifier.citedreferenceSalem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic‐induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017; 15 ( 5 ): 789 – 98.
dc.identifier.citedreferenceAppendix 5, Validity of outcome measures. In: Aripiprazole Prolonged Release Suspension for Injection (Abilify Maintena) (300 Mg and 400 Mg Vial). CADTH Common Drug Reviews. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2017. Available from https://www.ncbi.nlm.nih.gov/books/NBK447744/. Accessed April 27, 2019.
dc.identifier.citedreferenceLeucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second‐generation versus first‐generation antipsychotic drugs for schizophrenia: a meta‐analysis. Lancet Lond Engl 2009; 373 ( 9657 ): 31 – 41.
dc.identifier.citedreferenceLindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder—a systematic review and meta‐analysis. J Affect Disord 2017; 213: 138 – 50.
dc.identifier.citedreferenceMeltzer HY. What’s atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004; 4 ( 1 ): 53 – 7.
dc.identifier.citedreferenceKumar R, Sachdev PS. Akathisia and second‐generation antipsychotic drugs. Curr Opin Psychiatry 2009; 22 ( 3 ): 293 – 9.
dc.identifier.citedreferenceLeucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple‐treatments meta‐analysis. Lancet 2013; 382 ( 9896 ): 951 – 62.
dc.identifier.citedreferenceCitrome L. Activating and sedating adverse effects of second‐generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 2017; 37 ( 2 ): 138 – 47.
dc.identifier.citedreferencePeluso MJ, Lewis SW, Barnes TRE, Jones PB. Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. Br J Psychiatry 2012; 200 ( 5 ): 387 – 92.
dc.identifier.citedreferenceRummel‐Kluge C, Komossa K, Schwarz S, et al. Second‐generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta‐analysis of head‐to‐head comparisons. Schizophr Bull 2012; 38 ( 1 ): 167 – 77.
dc.identifier.citedreferenceOtsuka America Pharmaceutical Inc. Abilify (Aripiprazole) [Package Insert]. Rockville, MD: Otsuka America Pharmaceutical Inc., 2018.
dc.identifier.citedreferenceOtsuka Pharmaceutical Co. Abilify Maintena (Aripiprazole) [Package Insert]. Rockville, MD: Otsuka Pharmaceutical Co., 2019.
dc.identifier.citedreferenceAllergan Inc. Saphris (Asenapine) [Package Insert]. Irvine, CA: Allergan Inc., 2017.
dc.identifier.citedreferenceOtsuka Pharmaceutical Co. Rexulti (Brexpiprazole) [Package Insert]. Rockville, MD: Otsuka Pharmaceutical Co., 2018.
dc.identifier.citedreferenceAllergan USA, Inc. Vraylar (Cariprazine) [Package Insert]. Madison, NJ: Allergan USA, Inc., 2018.
dc.identifier.citedreferenceMylan Pharmaceuticals, Inc. Iloperidone [Package Insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc., 2019.
dc.identifier.citedreferenceSunovion Pharmaceuticals Inc. Latuda (Lurasidone) [Package Insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc., 2018.
dc.identifier.citedreferenceNorthStar Rx LLC. Paliperidone [Package Insert]. Memphis, TN: NorthStar Rx LLC, 2018.
dc.identifier.citedreferenceJanssen Pharmaceuticals, Inc. Invega Sustenna (Paliperidone Palmitate) [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2017.
dc.identifier.citedreferenceJanssen Pharmaceutical, Inc. Risperidone [Package Insert]. Horsham, PA: Janssen Pharmaceutical, Inc., 2019.
dc.identifier.citedreferenceJanssen Pharmaceuticals, Inc. Risperdal Consta (Risperdone LAI) [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2007.
dc.identifier.citedreferencePfizer Inc. Geodon (Ziprasidone) [Package Insert]. New York, NY: Pfizer Inc., 2018.
dc.identifier.citedreferenceGardner DM, Murphy AL, O’Donnell H, Pharm B, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167 ( 6 ): 686 – 93.
dc.identifier.citedreferenceBarnes TR. A rating scale for drug‐induced akathisia. Br J Psychiatry 1989; 154: 672 – 6.
dc.identifier.citedreferenceEl‐Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;( 2 ): CD004578.
dc.identifier.citedreferenceFleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double‐blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009; 65: 510 – 7.
dc.identifier.citedreferenceMcEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. A randomized, double‐blind, placebo‐controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007; 41 ( 11 ): 895 – 905.
dc.identifier.citedreferencePigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo‐controlled 26‐week study. J Clin Psychiatry 2003; 64 ( 9 ): 1048 – 56.
dc.identifier.citedreferenceMarder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short‐term, placebo‐controlled trials. Schizophr Res 2003; 61 ( 2 ): 123 – 36.
dc.identifier.citedreferenceCenter for Drug Evaluation and Research. Drug Approval Package: Abilify (Aripiprazole) NDA #21‐436. Medical Review(s). November 2002. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21‐436_Abilify.cfm. Accessed May 3, 2019.
dc.identifier.citedreferencePotkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60 ( 7 ): 681 – 90.
dc.identifier.citedreferenceKane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52‐week, multicenter, randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry 2012; 73 ( 5 ): 617 – 24.
dc.identifier.citedreferenceFleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once‐monthly for treatment of schizophrenia: double‐blind, randomised, non‐inferiority study. Br J Psychiatry J Ment Sci 2014; 205 ( 2 ): 135 – 44.
dc.identifier.citedreferenceKhanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014;( 1 ): CD006569.
dc.identifier.citedreferenceZimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double‐blind, 4‐week study. Int Clin Psychopharmacol 2007; 22 ( 6 ): 363 – 70.
dc.identifier.citedreferenceNasrallah HA, Newcomer JW, Risinger R, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry 2016; 77 ( 11 ): 1519 – 25.
dc.identifier.citedreferenceChrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long‐term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52‐week, open‐label comparison with olanzapine. Psychopharmacology 2006; 189 ( 2 ): 259 – 66.
dc.identifier.citedreferenceChan H‐Y, Lin W‐W, Lin S‐K, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007; 68 ( 1 ): 29 – 36.
dc.identifier.citedreferenceNasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Long‐term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr 2019; 24 ( 4 ): 395 – 403.
dc.identifier.citedreferenceAllergan Inc. Saphris (Asenapine) [Package Insert]. Irvine, CA: Allergan Inc., 2017.
dc.identifier.citedreferenceKane JM, Mackle M, Snow‐Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo‐controlled trial of asenapine for the prevention of relapse of schizophrenia after long‐term treatment. J Clin Psychiatry 2011; 72 ( 3 ): 349 – 55.
dc.identifier.citedreferenceMcIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long‐term treatment of bipolar disorder: a double‐blind 40‐week extension study. J Affect Disord 2010; 126 ( 3 ): 358 – 65.
dc.identifier.citedreferenceLandbloom R, Mackle M, Wu X, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double‐blind, fixed‐dose, placebo‐controlled trial with olanzapine as an active control. CNS Spectr 2017; 22 ( 4 ): 333 – 41.
dc.identifier.citedreferenceMcIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double‐blind, placebo‐controlled trial. J Affect Disord 2010; 122 ( 1 ): 27 – 38.
dc.identifier.citedreferenceLandbloom RL, Mackle M, Wu X, et al. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3‐week, randomized, double‐blind, placebo‐controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord 2016; 190: 103 – 10.
dc.identifier.citedreferenceKane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010; 30 ( 2 ): 106 – 15.
dc.identifier.citedreferenceKane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double‐blind, controlled phase 3 trial of fixed‐dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164 ( 1–3 ): 127 – 35.
dc.identifier.citedreferenceFleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and safety of brexpiprazole (OPC‐34712) as maintenance treatment in adults with schizophrenia: a randomized, double‐blind, placebo‐controlled study. Int J Neuropsychopharmacol 2017; 20 ( 1 ): 11 – 21.
dc.identifier.citedreferenceThase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double‐blind study. J Clin Psychiatry 2015; 76 ( 9 ): 1232 – 40.
dc.identifier.citedreferenceThase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo‐controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224 – 31.
dc.identifier.citedreferenceStudy to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC‐34712 and Aripiprazole for Treatment of Acute Schizophrenia – Full Text View – ClinicalTrials.gov. Available from https://clinicaltrials.gov/ct2/show/NCT00905307. Accessed April 28, 2019.
dc.identifier.citedreferenceOtsuka Pharmaceutical Development & Commercialization, Inc. Multicenter, Open‐label, Safety and Tolerability Study (STEP 210). Available from https://clinicaltrials.gov/ct2/show/NCT01649557. Identifier: NCT01649557. Accessed May 30, 2019.
dc.identifier.citedreferenceCorrell CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6‐week randomized, double‐blind, placebo‐controlled trial. Am J Psychiatry 2015; 172 ( 9 ): 870 – 80.
dc.identifier.citedreferenceForbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A long‐term, open‐label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol 2018; 21 ( 5 ): 433 – 41.
dc.identifier.citedreferenceDurgam S, Earley W, Lipschitz A, et al. An 8‐week randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 2016; 173 ( 3 ): 271 – 81.
dc.identifier.citedreferenceDurgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 2014; 152 ( 2–3 ): 450 – 7.
dc.identifier.citedreferenceDurgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed‐dose, phase 3, randomized, double‐blind, placebo‐ and active‐controlled trial. J Clin Psychiatry 2015; 76 ( 12 ): e1574 – 82.
dc.identifier.citedreferenceSachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double‐blind, placebo‐controlled, phase III trial. J Affect Disord 2015; 174: 296 – 302.
dc.identifier.citedreferenceDurgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof‐of‐concept trial. Int Clin Psychopharmacol 2016; 31 ( 2 ): 61 – 8.
dc.identifier.citedreferenceNémeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double‐blind, controlled trial. Lancet 2017; 389 ( 10074 ): 1103 – 13.
dc.identifier.citedreferenceDurgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double‐blind, placebo‐controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016; 77 ( 3 ): 371 – 8.
dc.identifier.citedreferenceKane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 2015; 35 ( 4 ): 367 – 73.
dc.identifier.citedreferenceCalabrese JR, Keck PE, Starace A, et al. Efficacy and safety of low‐ and high‐dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double‐blind, placebo‐controlled study. J Clin Psychiatry 2015; 76 ( 3 ): 284 – 92.
dc.identifier.citedreferenceCutler AJ, Durgam S, Wang Y, et al. Evaluation of the long‐term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1‐year open‐label study. CNS Spectr 2018; 23 ( 1 ): 39 – 50.
dc.identifier.citedreferenceWeiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual‐ or immediate‐switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res 2014; 153 ( 1–3 ): 160 – 8.
dc.identifier.citedreferenceWeiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6‐week acute‐phase pivotal trials. J Clin Psychopharmacol 2008; 28 ( 2 suppl 1 ): S12 – 19.
dc.identifier.citedreferenceCutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four‐week, double‐blind, placebo‐ and ziprasidone‐controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008; 28 ( suppl 1 ): S20 – 8.
dc.identifier.citedreferenceKane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long‐term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008; 28 ( suppl 1 ): S29 – 35.
dc.identifier.citedreferenceCutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long‐term safety and tolerability of iloperidone: results from a 25‐week, open‐label extension trial. CNS Spectr 2013; 18 ( 1 ): 43 – 54.
dc.identifier.citedreferenceWeiden PJ, Manning R, Wolfgang CD, et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS Drugs 2016; 30 ( 8 ): 735 – 47.
dc.identifier.citedreferencePotkin SG, Kimura T, Guarino J. A 6‐week, double‐blind, placebo‐ and haloperidol‐controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol 2015; 5 ( 6 ): 322 – 31.
dc.identifier.citedreferenceLoebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double‐blind, placebo‐controlled trial in patients with schizophrenia. CNS Spectr 2014; 19 ( 2 ): 197 – 205.
dc.identifier.citedreferenceStahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6‐month, open‐label, extension study. J Clin Psychiatry 2013; 74 ( 5 ): 507 – 15.
dc.identifier.citedreferenceLoebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12‐month, double‐blind, noninferiority study. Schizophr Res 2013; 147 ( 1 ): 95 – 102.
dc.identifier.citedreferenceLoebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double‐blind, placebo‐ and active‐controlled trial. Schizophr Res 2013; 145 ( 1–3 ): 101 – 9.
dc.identifier.citedreferenceCorrell CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long‐term safety and effectiveness of lurasidone in schizophrenia: a 22‐month, open‐label extension study. CNS Spectr 2016; 21 ( 5 ): 393 – 402.
dc.identifier.citedreferenceCitrome L, Cucchiaro J, Sarma K, et al. Long‐term safety and tolerability of lurasidone in schizophrenia: a 12‐month, double‐blind, active‐controlled study. Int Clin Psychopharmacol 2012; 27 ( 3 ): 165 – 76.
dc.identifier.citedreferenceLoebel A, Silva R, Goldman R, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo‐controlled study. J Clin Psychiatry 2016; 77 ( 12 ): 1672 – 80.
dc.identifier.citedreferenceNasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6‐week, randomized, placebo‐controlled study. J Psychiatr Res 2013; 47 ( 5 ): 670 – 7.
dc.identifier.citedreferenceCalabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017; 27 ( 9 ): 865 – 76.
dc.identifier.citedreferenceWeiden PJ. EPS profiles: the atypical antipsychotics: are not all the same. J Psychiatr Pract 2007; 13 ( 1 ): 13 – 24.
dc.identifier.citedreferenceOgasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6‐week, placebo‐controlled study. Psychopharmacology 2013; 225 ( 3 ): 519 – 30.
dc.identifier.citedreferenceMeltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double‐blind, placebo‐ and olanzapine‐controlled study. Am J Psychiatry 2011; 168 ( 9 ): 957 – 67.
dc.identifier.citedreferenceLoebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double‐blind, placebo‐controlled study. Am J Psychiatry 2014; 171 ( 2 ): 160 – 8.
dc.identifier.citedreferenceFleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long‐acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012; 15 ( 1 ): 107 – 18.
dc.identifier.citedreferenceGopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double‐blind, placebo‐controlled, dose‐response study. Int Clin Psychopharmacol 2010; 25 ( 5 ): 247 – 56.
dc.identifier.citedreferenceMeltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended‐release tablets in the treatment of acute schizophrenia: pooled data from three 6‐week, placebo‐controlled studies. J Clin Psychiatry 2008; 69 ( 5 ): 817 – 29.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar2404_am.pdf
Size:
261.7KB
Format:
PDF
View/Open
Name:
phar2404.pdf
Size:
117.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.